Valneva in the green after its annual turnover

(AOF) – Valneva gained 1.3% to 15.47 euros at the start of the session after the publication of its 2021 turnover and the first financial elements for the 2022 financial year. Last year, the laboratory specializing in vaccines against rare diseases, and whose vaccine against Covid is awaiting approval, achieved a turnover of 348.1 million euros, an increase of 216%. It includes 253.3 million Covid-related revenues under the (now terminated) agreement with the British government.

The turnover also includes 94.8 million from product sales and Other Revenue (excluding Covid), which corresponds to the upper part of the forecast range previously communicated by the company, namely 85 to 100 million.

For fiscal 2012, Valneva expects total sales of between 430 and 590 million, including 350 to 500 million from sales of the Covid-19 vaccine, subject to regulatory approvals and deliveries.

As of December 31, the company’s cash amounted to 346.7 million.

“With nearly €350 million in cash, we entered 2022 from a strong position and we will continue to focus on obtaining regulatory approvals and preparing for market entry of products from our programs- in the final stages of development,” commented Peter Bühler, Chief Financial Officer of Valneva.

©
AOF

The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors in no way guarantee the absence of error and defects, even hidden ones, nor the exhaustive character or the lack of conformity for any use whatsoever of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.



Reference-www.capital.fr

Author Image
cem_wpadmin

Leave a Reply

Your email address will not be published.